Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.

PMID:
12545140
2.

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Dahri K, Ensom MH.

Clin Pharmacokinet. 2007;46(2):109-32. Review.

PMID:
17253884
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

[Evidence-based therapeutic drug monitoring for efavirenz].

Solas C, Gagnieu MC; roupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):197-205. doi: 10.2515/therapie/2011033. Epub 2011 Aug 9. Review. French.

PMID:
21819803
5.

Efavirenz.

Adkins JC, Noble S.

Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. Review.

PMID:
9878993
6.

Efavirenz for HIV-1 infection in adults: an overview.

Fortin C, Joly V.

Expert Rev Anti Infect Ther. 2004 Oct;2(5):671-84. Review.

PMID:
15482231
7.

Efavirenz: a review.

Vrouenraets SM, Wit FW, van Tongeren J, Lange JM.

Expert Opin Pharmacother. 2007 Apr;8(6):851-71. Review.

PMID:
17425480
8.

Dose-ranging studies.

Manion D.

Int J Clin Pract Suppl. 1999 Jun;103:8-9. Review.

PMID:
10622036
9.

Antiretroviral pharmacokinetics in the paediatric population: a review.

King JR, Kimberlin DW, Aldrovandi GM, Acosta EP.

Clin Pharmacokinet. 2002;41(14):1115-33. Review.

PMID:
12405863
10.

Human genetic variability and HIV treatment response.

Haas DW.

Curr HIV/AIDS Rep. 2006 Jul;3(2):53-8. Review.

PMID:
16608660
11.

Efavirenz: enhancing the gold standard.

Arribas JR.

Int J STD AIDS. 2003 Oct;14 Suppl 1:6-14. Review.

PMID:
14617398
12.

Efavirenz-associated gynecomastia: report of five cases and review of the literature.

Jover F, Cuadrado JM, Roig P, Rodríguez M, Andreu L, Merino J.

Breast J. 2004 May-Jun;10(3):244-6. Review.

PMID:
15125753
13.

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries.

Gorowara M, Burger D, Hill A, Ruxrungtham K.

Curr Opin HIV AIDS. 2010 Jan;5(1):90-6. doi: 10.1097/COH.0b013e3283339caf. Review.

PMID:
20046153
14.

Efavirenz.

Porche DJ.

J Assoc Nurses AIDS Care. 2000 May-Jun;11(3):95-8. Review. No abstract available.

PMID:
10826308
15.

Clinical impact of patient population differences and genomic variation in efavirenz therapy.

King J, Aberg JA.

AIDS. 2008 Sep 12;22(14):1709-17. doi: 10.1097/QAD.0b013e32830163ad. Review.

PMID:
18753940
16.

Paediatric treatment issues.

Walters S.

Int J Clin Pract Suppl. 1999 Jun;103:26-9. Review.

PMID:
10622040
17.

Central nervous system adverse effects with efavirenz: case report and review.

Puzantian T.

Pharmacotherapy. 2002 Jul;22(7):930-3. Review.

PMID:
12126226
18.

A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature.

Robertson SM, Penzak SR, Lane J, Pau AK, Mican JM.

Clin Infect Dis. 2005 Jul 15;41(2):e15-8. Epub 2005 Jun 7. Review.

PMID:
15983905
19.

An appraisal of antiretroviral drugs in hemodialysis.

Izzedine H, Launay-Vacher V, Baumelou A, Deray G.

Kidney Int. 2001 Sep;60(3):821-30. Review.

20.

Neuropsychiatric complications of antiretroviral therapy.

Cespedes MS, Aberg JA.

Drug Saf. 2006;29(10):865-74. Review.

PMID:
16970510

Supplemental Content

Support Center